Biochemical pathways of copper complexes: progress over the past 5 years.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
20
09
2020
revised:
06
01
2021
accepted:
12
01
2021
pubmed:
25
1
2021
medline:
22
1
2022
entrez:
24
1
2021
Statut:
ppublish
Résumé
Copper is an essential trace element with vital roles in many metalloenzymes; it is also prominent among nonplatinum anticancer metallodrugs. Copper-based complexes are endogenously biocompatible, tenfold more potent than cisplatin, exhibit fewer adverse effects, and have a wide therapeutic window. In cancer biology, copper acts as an antitumor agent by inhibiting cancer via multiple pathways. Herein, we present an overview of advances in copper complexes as 'lead' antitumor drug candidates, and in understanding their biochemical and pharmacological pathways over the past 5 years. This review will help to develop more efficacious therapeutics to improve clinical outcomes for cancer treatments.
Identifiants
pubmed: 33486113
pii: S1359-6446(21)00044-1
doi: 10.1016/j.drudis.2021.01.015
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Coordination Complexes
0
Trace Elements
0
Copper
789U1901C5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1096Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.